CIDP Serum

Human CIDP Serum for Autoimmune Peripheral Neuropathy Research

Our CIDP Serum is sourced from IRB-consented donors clinically diagnosed with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP, also referred to as chronic inflammatory demyelinating polyneuropathy). Each sample is processed and frozen within 24 hours of collection to ensure consistency and high quality for immunological and neurological research. CIDP is an immune-mediated autoimmune disorder of the peripheral nervous system in which the immune system attacks myelin and the nodal region of peripheral nerves, producing progressive or relapsing weakness and sensory loss with demyelinating features on nerve conduction study.

Why Serum for CIDP Research

• The therapeutic response to plasma exchange and to intravenous immunoglobulin is itself evidence that a circulating humoral factor contributes to CIDP. Serum is the specimen in which that factor is sought.
• A defined subset of patients previously grouped under CIDP carry autoantibodies against nodal and paranodal proteins — neurofascin-155, contactin-1 and Caspr1 — and are now classified separately as autoimmune nodopathies. These antibodies are typically of the IgG4 subclass, are detected in serum, and are associated with a poor response to intravenous immunoglobulin.
• IgG subclass determination matters mechanistically: IgG4 antibodies do not fix complement and act instead by disrupting protein-protein interactions, which distinguishes nodopathy biology from complement-dependent demyelination. This distinction is made serologically.
• Complement activation contributes to macrophage-mediated demyelination in CIDP, and complement components and activation products are measurable in serum — relevant as complement-directed and FcRn-targeted therapeutic approaches are investigated in this disease.
• Neurofilament light chain in serum is an established marker of axonal injury across neurological disease and provides a means of assessing the axonal component of CIDP, which is the principal driver of irreversible disability.
• Serum is anticoagulant-free, which is required for the autoantibody immunoassays, cell-based assays and immunohistochemical binding studies used to characterise neuropathy-associated antibodies.

Donor Stratification Available

• CIDP variant: typical CIDP, distal, multifocal, focal, motor or sensory presentation where classified
• Nodal and paranodal autoantibody status where tested, including neurofascin-155 and contactin-1
• Disability and disease activity by INCAT or comparable instrument where recorded
• Treatment status: treatment-naive, on intravenous or subcutaneous immunoglobulin, on corticosteroids, on plasma exchange, on other immunosuppressant, or in washout
• Treatment responsiveness: immunoglobulin-responsive versus refractory
• Disease course (progressive versus relapsing) and disease duration
• Matched healthy controls available

Product Features

• Collected from clinically confirmed CIDP donors
• Research Use Only (RUO)
• Processed and frozen within 24 hours of collection
• IRB-approved protocols with documented consent
• Custom aliquot volumes available upon request
• Larger volumes and serial collections available by request

De-identified Donor Data

• Diagnosis confirmation
• Age, sex assigned at birth, and race/ethnicity
• Donor-reported medical history and comorbidities
• Treatment history and disease course where available
• Additional CIDP-specific metadata available on request

Applications

• Nodal and paranodal autoantibody detection and assay development
• IgG subclass and antibody characterisation studies
• Complement activation and complement-directed therapeutic research
• Neurofilament light chain measurement for axonal injury research
• Cell-based and tissue binding assays using patient serum as the antibody source
• Serum cytokine and inflammatory protein profiling
• Biomarker discovery for treatment response and immunoglobulin dependence
• Therapeutic candidate screening and target validation in autoimmune neuropathy

Other CIDP Specimen Types

• CIDP Plasma
• CIDP Whole Blood
• CIDP PBMC
• CIDP Leukopak

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
• Documentation support available for regulatory review

Ordering & Customization

CIDP serum is available in standard and custom volumes. For pricing, availability, or to discuss a cohort stratified by variant or antibody status, email learnmore@sanguinebio.com. For international orders or documentation requirements, please contact us to ensure compatibility with your country’s regulations. To browse serum across all disease states and healthy donors, visit our human serum page.